FDA Nears Decision on MDMA Therapy for PTSD
TL;DR Summary
FDA advisors are debating whether to recommend MDMA-assisted therapy for PTSD, highlighting concerns about clinical research shortcomings, potential abuse, and allegations of misconduct in trials. Despite positive findings from Lykos Therapeutics' studies, issues like "functional unblinding" and long-term data reliability are under scrutiny. The decision could mark a significant step for psychedelic treatments in mainstream healthcare.
- FDA considers MDMA therapy for PTSD at advisory meeting : Shots - Health News NPR
- FDA advisers consider MDMA therapy to treat PTSD CNN
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
- With MDMA on brink of FDA approval, psychedelic medicine faces critical moment MarketWatch
- Ecstasy as a PTSD treatment? The FDA is set to decide. POLITICO
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
6 min
vs 6 min read
Condensed
95%
1,185 → 56 words
Want the full story? Read the original article
Read on NPR